Studies in several cancers showed that CTCs expose immune checkpoints such as PD-L1, PD-L2, and CTLA-4 on their membrane, so they have been evaluated as biomarkers to identify patients suitable for immunotherapy [103]. This evidence concerns the gene CD274 and cancer.